July 15, 2025

Supplementary Data S1 from Mechanism of Initial Favorable Response to Decitabine in TP53-Mutated MDS/AML and Potential Mechanisms of Subsequent Relapse

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Clinical data highlights initial response to decitabine in patients with TP53 mutations, suggesting underlying mechanisms for relapse.

MAIN FINDING: Decitabine shows initial favorable response in patients with TP53-mutated MDS and AML.
KEY EVIDENCE: Clinical data indicates a significant response rate among participants treated with decitabine.
APPROACH: The study analyzes clinical trial data to understand the effectiveness of decitabine in specific mutations.
SIGNIFICANCE: Understanding relapse mechanisms can guide future therapies for MDS and AML patients.
],

Ng et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark